Ensidipine targeted drug survival rate

Enasidenib is a targeted drug mainly used to treat patients with acute myeloid leukemia (AML) who carry IDH2 gene mutations.

In multiple clinical trials, the overall response rate of ensidipine in patients with AML carrying IDH2 gene mutations is usually around 40%. This means that approximately 40% of patients treated with ensidipine experienced significant remission.

Complete response rates to ensidipine vary across clinical trials, but are generally around 20%. Complete remission refers to the complete disappearance of all symptoms of the patient's disease and no recurrence within a certain period of time.

Median survival was generally longer in patients treated with ensidipine, which varied from trial to trial but generally ranged from 9 months to 20 months. This means that half of the patients treated with ensidipine survived beyond this time frame.

Different patients' physical conditions, disease severity, tolerance and responsiveness to drugs, and other factors will affect the therapeutic effect of ensidipine, thereby affecting the survival rate. Ensidipine is usually used in combination with other treatments (such as chemotherapy, radiotherapy, etc.) to improve the therapeutic effect. The choice and implementation of treatment options can also affect patient survival. AML is a highly heterogeneous disease, and the patient's disease status and progression rate will also affect the therapeutic effect and survival rate of ensidipine.

Ensidipine, as a targeted therapy, is useful in the treatment of AML carrying IDH2 gene mutations.It has shown significant efficacy in patients and can improve the overall response rate, complete response rate and median survival time of patients. However, survival rates are affected by multiple factors, including individual patient differences, treatment regimen, and disease status. Therefore, when receiving ensidipine treatment, patients should pay close attention to their own conditions, maintain good communication with their doctors, and follow the doctor's recommendations for treatment and monitoring

References:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml